MTA1 and prostate cancer: Kai et al. identified MTA1 as a component of a bone metastasis signature in prostate cancer, and MTA1-knockdown cells expressed lower levels of vascular endothelial growth factor (VEGF) and displayed decreased angiogenicity both in vitro and in vivo [27], suggesting that MTA1 upregulates VEGF expression, in agreement with Du et al. [19].